Venture • Life Science

Ampersand Capital Partners Invests In Vernal Biosciences

On June 2, 2022, growth capital firm Ampersand Capital Partners invested in life science company Vernal Biosciences

Investment Context
  • This is Ampersand Capital Partners’ 35th transaction in the Life Science sector.
  • This is Ampersand Capital Partners’ 60th transaction in the United States.
  • This is Ampersand Capital Partners’ 1st transaction in Vermont.

Explore All 557 Venture Life Science Deals - Search the Database Free


Investment Summary

Date June 2, 2022
Target Vernal Biosciences
Sector Life Science
Investor(s) Ampersand Capital Partners
Deal Type Venture

Target Company

Vernal Biosciences

Colchester, Vermont, United States
Vernal Biosciences provides mRNA and LNP-mRNA manufacturing services to democratize the use of mRNA for all use cases ranging from drug discovery to clinical development across all use cases such as gene editing and regulation, cellular programming, vaccines, mRNA replacement, oncology, autoimmune, and protein degradation. Vernal Biosciences is based in Colchester, Vermont.
Explore More Deals

Browse All 215,262 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investor Overview 1

Investor

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


Deal Context for Investor #
Overall 71 of 86
Sector: Life Science 35 of 43
Type: Venture 11 of 11
State: Vermont 1 of 1
Country: United States 60 of 70
Year: 2022 6 of 11
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-21 ALPCO

Salem, New Hampshire, United States

ALPCO is an importer and distributor of immunoassay-based products for the North American life science markets. ALPCO is a provider of proprietary and distributed diagnostics solutions, with over 60 collaborating partners from around the globe. ALPCO was founded in 1990 and is based in Salem, New Hampshire.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-23 Vantage MedTech

Moonachie, New Jersey, United States

Vantage MedTech is a provider of custom electromechanical and software solutions for the medical device industry. Vantage MedTech was founded in 1998 and is based in Moonachie, New Jersey.

Buy -